The Association of American Physicians and Surgeons (AAPS) revealed on Wednesday that the pandemic fears are still running high after more than a year of public health exhortations and 168m doses of COVID-19 vaccines.
The public health officials and vaccine makers acknowledge that the hygiene products have not been shown to prevent disease transmission. The masking and social distancing are not supported by randomized controlled trials and have not ended the pandemic, added AAPS.
Based on the Centers for Disease Control and Prevention's (CDC) updated guidance on disinfecting surfaces, there is little scientific support for routine use of disinfectants in community settings, whether indoor or outdoor, to prevent SARS-CoV-2 transmission from fomites.
In a Bangladeshi randomized controlled trial with 606 subjects, the use of 1% povidone iodine in eye/nose drops and mouth gargle reduced COVID-19 hospitalizations by 84% and mortality by 88%, notes AAPS.
Both Israel and New Zealand have approved the use of a nitric oxide nasal spray that helps prevent COVID infection and transmission. It will be sold over the counter. A randomized controlled trial in confirmed COVID cases in the UK showed that the nasal spray reduced the viral load by 95% in the first 24 hours and 99% within 72 hours, concluded AAPS.
PureTech Health reports positive Phase 1b data for LYT-200 in MDS and AML
Natera showcases Prospera transplant data across 17 presentations at ISHLT 2026
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Ondine Biomedical abstracts selected for 2026 World Congress on Infectious Diseases
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
FDA extends review timeline for Sanofi's Sarclisa subcutaneous formulation in multiple myeloma
hVIVO secures Phase III human challenge trial contract with ILiAD Biotechnologies
FDA expands approval of Sanofi's Tzield for early-stage type 1 diabetes in young children
Inhibrx provides clinical update on ozekibart (INBRX-109) for colorectal cancer treatment
Lytix reports phase II results showing durable responses in advanced melanoma
Rznomics reports RZ-001 interim clinical data in hepatocellular carcinoma at AACR 2026
Akeso presents positive Phase II results from cadonilimab combination study at AACR 2026
GSK secures China approval for Blenrep in relapsed multiple myeloma